For your adult patients with relapsed
or refractory multiple myeloma
WITH SARCLISA + Kd1-5
Longest ever reported
in a phase 3 trial that included lenalidomide-refractory patients*
*Based on a review of published phase 3 trials that included lenalidomide-refractory patients with RRMM. Interpret with caution, as various factors, including patient population, differ between trials.
IKEMA mPFS: 41.7 months with SARCLISA + Kd (n=179) vs 20.8 months with Kd alone (n=123), HR=0.59 (95% CI: 0.42, 0.83) at a median follow-up of 44 months
Superior PFS vs Kd at
(median follow-up of 20.7 months)1
SARCLISA + Kd: mPFS NR
Kd: mPFS 20.27 months1
(95% CI: 0.37, 0.82; P=0.0032)1
See the final mPFS analysis from the IKEMA trialExplore sarclisa + Kd
Consider sarclisa + Kd
Explore Patient Types
See the anti-CD38 monoclonal
Explore the MOA
antibody of SARCLISA1
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
for Multiple Myeloma recommend isatuximab-irfc (sarclisa) as a Category 1 Preferred option for early relapses6†
- In combination with pomalidomide and dexamethasone‡
- In combination with carfilzomib and dexamethasone
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
†1-3 prior therapies.6 Recommendation for isatuximab-irfc (SARCLISA) in combination with carfilzomib and dexamethasone based on results of interim analysis.
‡After 2 prior therapies including lenalidomide and a proteasome inhibitor.6
Kd=carfilzomib and dexamethasone; MOA=mechanism of action; mPFS=median progression-free survival; NCCN=National Comprehensive Cancer Network (NCCN®); NR=not reached; PFS=progression-free survival; RRMM=relapsed or refractory multiple myeloma.